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Abstract  
BACKGROUND: Von Willebrand disease (vWD) is an inherited hemostatic disorder that affects the 
hemostasis pathway. The worldwide prevalence of vWD is estimated to be 1% of the general 
population but only 0.002% in Malaysia.  
AIM: Our present paper has been written to disclose the statistical counts on the number of vWD 
cases reported from 2011 to 2013.  
MATERIAL AND METHODS: This article is based on sociodemographic data, diagnoses and 
laboratory findings of vWD in Malaysia. A total of 92 patients were reported to have vWD in 
Malaysia from 2011 to 2013.  
RESULTS: Sociodemographic-analysis revealed that 60% were females, 63% were of the Malay 
ethnicity, 41.3% were in the 19-44 year old age group and 15.2% were from Sabah, with the East 
region having the highest registered number of vWD cases. In Malaysia, most patients are 
predominately affected by vWD type 1 (77.2%). Factor 8, von Willebrand factor: Antigen and vWF: 
Collagen-Binding was the strongest determinants in the laboratory profiles of vWD.  
CONCLUSION: This report has been done with great interest to provide an immense contribution 
from Malaysia, by revealing the statistical counts on vWD from 2011-2013. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Malaysia is one of the wealthiest and most 
developed countries in Southeast Asia with 
widespread and systematic healthcare system. The 
healthcare sector in Malaysia is primarily operated by 
the Ministry of Health Malaysia (MOH), established 
under Malaysian government [1].
 
In reviewing the 
Malaysian Health Profiles, coronary heart disease, 
stroke and respiratory illness are the leading causes 
of death, as recorded by the World Health 
Organization (WHO) in 2011, among 50 major 
etiologies of deaths [2]. Hospitals in Malaysia are very 
much dedicated in providing the most current 
advanced interventions to patients to save their lives 
from the deadliest diseases and to promote quality 
treatments. Hereditary hematological disorders affect 
the blood, and the diagnosis of such cases is more 
complicated due to the involvement of genes in the 
deoxyribonucleic acid (DNA) that interrupt the working 
mechanisms of blood clotting factors. Based on the 
recent update from the National Blood Centre (PDN) 
of Malaysia, there are only a few men and women 
suffering from these diseases, leading to the 
conclusion that the impact of these diseases is 
relatively low among Malaysians. PDN was officially 
built under public sector to provide expert medical 
services and a foundation for research in the field of 
hematology. PDN has also received accreditation 
from National Association of Testing Authorities 
(NATA), Australia for ISO/ IEC 17025 and 
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specialization in 17 different fields related to blood-
associated diagnoses, resulting in quality medical 
outputs [3]. There are a few inherited hemostatic 
disorder cases reported by PDN repetitively every 
year, including Hemophilia, Von Willebrand disease 
(vWD), Bernard-Soulier Syndrome, adenosine 
diphosphate (ADP) receptor defect, Glanzmann 
Thrombasthenia and Factors deficiencies. PDN 
reports reveal that Hemophilia and vWD are the two 
major hemostatic disorders recorded at a high 
frequency level nationwide.  
A mutation in the von willebrand factor (vWF) 
gene is the main cause of vWD. The vWF gene 
supplies crucial signals to form vWF blood-clotting 
proteins, which trigger the formation of blood clots. 
vWF acts as a sticky glue to hold the blood clots 
together in preventing excessive blood loss. At the 
same time, abnormal blood clotting causes prolonged 
bleeding episodes in vWD. Although the public 
attention towards global health has grown quickly over 
the past half century, the understanding and 
awareness of Malaysians towards hereditary 
hemostatic diseases are still considered to be poor in 
comparison with other ASEAN countries.  
More needs to be done to coordinate 
Malaysians in order to improve the consciousness 
about these inherited hemostatic disorders. A total of 
five hundred fifty-four cases of vWD were reported in 
the PDN hemorrhagic disorders registry from 1979 to 
2013. Five hundred seventy-two vWD events were 
registered in Malaysia as of 2013. In Malaysia, many 
campaigns, colloquia and conferences have been 
organized, but to date, there are no updates or 
published evidence surveying the statistics of vWD 
over the last 3 years.  
Our present paper aims to disclose the 
statistic counts or percentages on vWD in Malaysia 
and to provide the report for the past 3 years, from 
2011 to 2013, regarding the age, gender, race, region 
and diagnosis (approved by MOH). This report is a 
contribution from Malaysia with the clinical description 
of vWD to the countries all over the world.  
 
 
Material and Methods 
 
Prior to commencing the study, ethical 
clearance was obtained from the Medical Research & 
Ethics Committee from National Medical Research 
Registry (NMRR). This study has been registered with 
NMRR and the research identification number is 
NMRR-13-873-17276. The vWD patient entries in the 
PDN registry are from various hospitals across 
Malaysia. Reports on the statistics were prepared 
between 2011 and 2013 and included selected 
demographic profiles (age, gender, ethnicity, state, 
region) and other data including vWD classification, 
year of diagnosis (2011-2013) and laboratory findings 
includes [Factor 8 (FVIII), vWF: Antigen (vWF: Ag) 
and vWF: Collagen-Binding (vWF: CB)]. In our 
analyses, we categorized patients into 5 different age 
categories: (0-4), (5-13), (14-18), (19-44) and (45 and 
above) years old.  
Ethnicities were classified based on the major 
populations of Malaysia, which are Malay, Chinese, 
and Indian, followed by Kadazan and Dusun, that 
distinguished in the ‘others’ category. Patients were 
also identified by their native states: eleven states 
(Perlis, Kedah, Pulau Pinang, Perak, Selangor, Negeri 
Sembilan, Melaka, Johor, Pahang, Terengganu, 
Kelantan) and 3 federal states (Wilayah Persekutuan, 
Sabah, Sarawak). All of the above listed states are 
divided into 2 separate regions, Peninsular Malaysia 
and East Malaysia.  
The classifications of vWD diagnosis were 
split into 3 different categories, listed as type 1, 2 and 
3. Laboratory findings expressed in percentages 
(FVIII, vWF: Ag and vWF: CB) were assigned into 5 
distinguished categories, below 10, 10-30, 31-60, 61-
100 and above 100. The data points were presented 
in percentages by using cross-tabulation between the 
demographic data. The independent t-test was 
applied to compare the mean and standard deviation 
(SD) of the diagnosis type and the laboratory findings. 
The statistical analysis was employed using SPSS 
version 18.0 software. Detailed data on the number of 
vWD incidences in Malaysia were solely provided by 
PDN.  
 
 
Results 
 
Sociodemographic characteristics 
Ninty-two patients between 1 and 52 years 
old who presented with vWD were recruited and 
diagnosed by PDN within 2011 to 2013. Out of 92 
patients, 40% were males and 60% were females. 
The majority of patients in this 3 year period were 
recorded in 2011 with 46 patients (35% of males and 
65% of females). In 2012, both genders registered in 
equivalent percentages. In 2013, the lowest number of 
cases was registered, with a total of 20 patients at a 
2:3 ratio of males to females (Fig. 1A).  
Cases of vWD were categorized into 6 
different age classifications. Patients between 19-44 
years old were most commonly diagnosed within 
these 3 years (41.3%), followed by patients 5-13 
years old (33.7%). Only 4.4% of registered patients 
were above 45 years old (Fig. 1B). The ethnicity 
distribution of the 92 total patients presenting with 
vWD to PDN in 2011 to 2013 is depicted in Fig. 1C. 
The majority of patients (63%) were the main ethnicity 
of Malaysia, Malay. Ethnicities falling under the 
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categories of ‘others,’ Indian and Chinese represented 
16.3%, 15.2% and 5.5% of the total, respectively.  
A) 
 
B) 
 
C) 
 
Figure 1: Percentages of gender, age category and ethnic 
distribution of vWD patients (n = 92) diagnosed in the PDN from 
2011 to 2013, respectively. The analyses were expressed in 
percentages using descriptive statistics 
 
States and Region 
The majority of patients were from Sabah in 
the East Malaysia region, representing an overall 
percentage of 15.2%, followed by Kedah in 13.0% of 
patients, and Wilayah Persekutuan in 12.0%. 
Noticeably, only 1.1% of patients diagnosed in PDN 
were from the Negeri Sembilan state in the 3 
consecutive years studied. Similarly, only 1 patient 
was considered to be of unknown origin (Fig. 2A). 
Eleven different states and 1 federal state comprise 
Peninsular Malaysia. The east coast region only 
consists of 2 distinct federal territories, Sabah and 
Sarawak. As for the overall analysis, most patients 
were from Peninsular Malaysia [74 (80.4%)], with only 
17 cases from the East Coast region (18.5%). 
Although the total area of East Coast region 
represents approximately 61% of the total land area of 
Malaysia, the highest sum of vWD cases were 
recorded in the peninsular region, as it contains the 
most states (12) and is comprised of 22 million 
residents Fig. 2B. 
A)
 
B)
 
 
Figure 2: Frequency of vWD patient native states, federal territories 
and regions, depicted in percentages. The figures illustrate the data 
of the patients diagnosed in the PDN for 3 consecutive years from 
2011 to 2013; n=92 
 
Classifications of vWD; Laboratory findings; 
Year of diagnosis  
The laboratory findings of each patient were 
depicted as percentages and the outcomes of each 
category were expressed as the mean (SD). It has 
been revealed that most patients are predominantly 
affected by vWD type 1 (77.2%) of patients throughout 
the 3 sequential years (2011-2013), with a mean (SD) 
value of 24 (7.23), as outlined in Fig. 3. The 
associations between types of vWD were strong 
factors influencing the laboratory findings. The highest 
prevalence recorded for all 3 distinct laboratory 
findings by groups of vWD patients was in the 31-60% 
group, with mean (SD) values as follows; FVIII: 11 
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(4.41), vWF:Ag: 13 (1.16) and vWF:CB: 13 (1.16). The 
next highest category was 10-30%, with mean (SD) 
values as follows; FVIII: 10 (7.64), vWF: Ag: 8 (6.56), 
vWF: CB: 8 (5.57).  
 
Figure 3: Classifications of vWD as Type 1, 2, and 3, and the 
laboratory findings of (FVIII, vWF: Ag, vWF: CB) based on the year 
of diagnosis (2011 to 2013). The outcome of the laboratory profiles 
classified into 5 different grades, below 10, 10-30, 31-60, 61-100, 
and above 100, is shown in percentages. The data were analyzed 
by the Independent t-test and are presented in means (SD); n=92 
 
 
Discussion 
 
The term vWD was coined by Finnish 
physician Eric Adolf von Willebrand in 1926. vWD is 
an inherited hemostatic disorder that affects the 
hemostasis pathway [1]. According to the recent 
annual global survey by the World Federation of 
Hemophilia updated in 2010, only 0.002% of vWD 
cases were reported among the population of 28 
million Malaysians. Apparently, the Malaysian 
Statistical Department website has posted that the 
population of Malaysia has increased to 30 million, 
and that the counts now represent 0.043% of the 
world population. The worldwide prevalence of vWD is 
estimated to be 1%, and based on our recent 
analysis, vWD cases are estimated to be found in 
0.002% of the total population [4]. PDN has diagnosed 
a total number of 554 cases of vWD from early 1979 
to 2013. Five hundred seventy-two vWD cases have 
been officially diagnosed and reported in the 
Malaysian Health registry, which comprises 554 cases 
in the PDN, 6 cases from University hospitals and 12 
cases diagnosed in state general hospitals.  
vWD arises from a defect due to abnormal 
vWF, which disrupts platelet aggregation 
mechanisms. vWF, formed between endothelial cells, 
is a large multimeric protein that helps platelets 
adhere and aggregate in order to facilitate hemostasis 
[5]. Ninety-two cases of vWD were recorded in 
patients between 1 to 52 years old from 2011 to 2013. 
The numbers of female patients recorded was 20% 
higher than the number of males. We have 
categorized the age of the patients into 6 distinct 
categories. This age classification was adapted from a 
previous report on Hemophilia in Singapore described 
by Kwa et al., [6]. The analysis showed that patients in 
the age category of 19-44 years old showed the 
highest number of registered vWD cases, with a total 
of 38.  
Although the Malaysian population comprises 
multiple ethnicities, the majority of the Malaysian 
population was of the native ethnicity, often referred to 
as the Malays or Bumiputeras. The prevalence of 
vWD cases was highest in Malays (63%) and lowest 
in Chinese (5.5%). The ratio of the overall number of 
events based on ethnicity for both sexes standardized 
by age and relative to Malay are as follows: (Chinese: 
Malay; 1:11), (Indian: Malay; 1: 4.1) and (Others: 
Malay; 1:3.9). The Indian population lived in Malaysia 
are comparatively lower than the Chinese population 
in Malaysia, with only 7.1% Indians in the total 
Malaysian population. Indian descendant are recorded 
as the second most common ethnicity affected by 
vWD. Malaysia is well-known as a multiracial country 
consisting of 3 major ethnicities, Malay, Chinese, 
Indian and others. The ethnicities that fall under the 
‘others’ category are Kadazan, Dusun, Iban, 
Minangkabau, Murut, Sikh, Bajau, Baba-Nyonya, 
Orang Asli, Dayak, Orang Ulu and Bidayuh. Based on 
our analysis, we found that of the ‘others’ category, 
only patients of the Kadazan and Dusun ethnicities 
has been diagnosed with vWD. Geographically, 
Malaysia is divided into 2 regions, Peninsular 
Malaysia and East Malaysia. Within these regions, 
Malaysia is divided again into 11 states and 3 federal 
territories. The majority of the vWD patients originated 
from Sabah, and this statement could be significantly 
correlated with the number of patients detected based 
on ethnicity. In Malaysia, the majority of the Kadazan 
and Dusun ethnicities originated from Sabah. 
Because other ethnic groups mostly lived in that state, 
together with the 3 major ethnic groups, this could 
explain why Sabah was reported to have the highest 
number of vWD cases.  
vWD is an inherited disorder, so most of the 
patients diagnosed in PDN were from the same 
family. We also understand that patients who 
categorized under their native places were subject to 
change locations, because many people tend to 
migrate due to personal needs or for work purposes. 
Classification of vWD, including Type 1, Type 2A, 2B, 
2 M, 2N, 3 and pseudo-type, based on the hereditary 
pattern, mechanism, prevalence in the general 
population, frequency of occurrence among vWD 
patients and bleeding tendency [7,8]. In Malaysia, 
among the majority of the 92 reported vWD patients, 
we encountered that the 97.9% of patients reported as 
having type 1 or 2 vWD, falling into the mild to 
moderate category. Subsequently, vWD type 3 
occurred in only 2.1% of cases. The clinical 
assessment of a person who has identified as a vWD 
patient should be classified and diagnosed according 
to their family history and laboratory profile outcomes. 
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In medical practice, laboratory diagnosis could vary 
according to the patient’s body and immune 
responses. Therefore, the laboratory profiles for vWD 
patients could be markedly different from the assumed 
and expected outcomes. These profiles are extremely 
dependent on the vWD classification, family history 
and response towards provided treatment [9-14]. 
In PDN, vWD patients were typically classified 
based on the 3 important laboratory findings: the 
assessment of FVIII, vWF: Ag and vWF: CB. These 
laboratory observations were categorized into 5 
different measurement levels, as mentioned above. 
Patients with laboratory measurements below 10% 
are considered to have extremely low levels and are 
categorized as cases that are very severe and rare, 
while measurements between 10-30%, 31-60%, or 
61-100% are assigned as severe to mild cases. 
Subsequently, levels above 100% are considered 
normal as type 1 vWD. In the 3 years studied, no 
mortality due to vWD was reported due to prolonged 
bleed. As for the overall view, no statistically 
significances were observed between gender, year of 
diagnosis or type of diagnosis. 
It was reported by Mohsin et al., that many 
cases of vWD remain undiagnosed due to various 
types of clinical manifestations and perplexing 
laboratory analysis. Patients who have insufficient 
amounts of vWF, less than 20 IU/dL, are most likely to 
have vWF gene mutations with significant bleeding 
tendencies [11, 15]. There are actually two different 
types of bleeding: mucocutaneous bleeding and 
traumatic bleeding. Mucocutaneous bleeding normally 
affects the mucous membranes, which are the 
delicate tissues lining the body passages such as the 
nose, mouth, uterus, vagina, stomach and intestines. 
This type of hemorrhages frequently occurs upon 
epistaxis, gingival bleeding, menorrhagia, 
gastrointestinal bleeding and superficial ecchymosis 
(bruising). In contrast, traumatic bleeding occurs due 
to surgery, childbirth, larger injuries and tooth 
extractions.  
There are two different types of treatment 
options that can be issued to vWD patients, 
desmopressin (DDAVP) and transfusion therapy, 
depending on the degree of severity and bleeding 
tendency. DDAVP is the standard form of therapy for 
patients experiencing Type 1 and 2A vWD. This drug 
mainly elevates the release of vWF and FVIII from 
endothelial cells and, in addition, increases the levels 
of vWF and FVIII:C by 3 to 5-fold. DDAVP can be 
administered intranasal and intravenously. In contrast, 
DDAVP is resistant and contradictory in patients with 
Type 2B vWD. This is due to their risk of developing 
thrombocytopenia. DDAVP has also been discovered 
to be an ineffective drug for Type 2N, 2 M and 3 vWD. 
Although antifibrinolytic (Tranexamic acid, epsilon-
aminocaproic acid) and plasma-based drug 
substances have not been widely been used to treat 
Type 1 vWD, these compounds are the mainstay to 
treat patients with type 2 and 3 vWD.  
Special cases that present with alloantibodies 
can be treated with recombinant FVIII and 
recombinant activated FVIII. Women undergoing 
heavy menstrual bleeding will usually be treated with 
oral contraceptive medications containing estrogen, 
which are more likely to be very effective in reducing 
the time frame of menorrhagia. For pregnant patients, 
they will be monitored accordingly to avoid excessive 
bleeding, especially during the initial postnatal weeks. 
Human-derived medium purity Factor VIII 
concentrates, which contain vWF, are available for 
patients undergoing surgical interventions with vWD 
complications. Humate P, Alphanate and Koate HP 
are also commercially available for prophylaxis of 
vWD. Platelet concentrates can be transfused for 
vWD patients categorized as having pseudo-type 
vWD, and blood transfusions can be given to prevent 
anemic and hypotensive cases among vWD patients 
[8, 11]. Many vWD patients in Malaysia only 
experience a mild form of this disease, which normally 
does not cause any serious hemorrhage. Patients 
identified under the severe category should seek 
emergency treatment to cease bleeding before it 
could become life-threatening. On the other hand, 
topical hemostatic agents such as thrombin, chitosan-
derivatives, floseal, lyostypt have also been employed 
extensively to stop the hemorrhage from any injuries. 
In conclusion, vWD is the second most 
common hemostatic disorder reported to occur in 
Malaysia, followed by Hemophilia. Our analysis has 
demonstrated important temporal changes in the 
demographics and the laboratory findings of vWD 
cases diagnosed in the PDN in Malaysia from 2011 to 
2013. A total of 92 vWD cases were registered in 
Malaysia from 2011 to 2013. In Malaysia, most 
patients are affected by type 1 vWD. In reviewing the 
patient’s sociodemographic characteristics, we 
noticed that most vWD cases occurred among 
females, patients of the Malay ethnicity and in the 19-
44 year old age group. The East region and Sabah 
state registered the highest number of vWD cases. 
This report has been done with great interest to 
provide an immense contribution from Malaysia, by 
revealing the statistical review on vWD. Based on this 
report, it seems apparent that the occurrence of vWD 
could be increasing along with the population of 
Malaysia; therefore, it is important to address the 
clinical care treatments for vWD patients before the 
disease becomes life-threatening. 
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